Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 7/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PYGM | P11217 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GLB1 | P16278 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14141099 | 1.00 | GBA1 (0.34) | GBA1LMNAPYGMSIPYGL | |
| SCHEMBL13478180 | 0.93 | GBA1 (0.38) | GBA1LMNAPYGMSIPYGL | |
| SCHEMBL18908426 | 0.93 | GBA1 (0.38) | GBA1LMNAPYGMSIPYGL | |
| SCHEMBL31003930 | 0.93 | GBA1 (0.38) | GBA1LMNAPYGMSIPYGL | |
| SCHEMBL13179879 | 0.93 | GBA1 (0.38) | GBA1LMNAPYGMSIPYGL | |
| SCHEMBL18916389 | 0.93 | GBA1 (0.38) | GBA1LMNAPYGMSIPYGL | |
| SCHEMBL29576792 | 0.93 | GBA1 (0.38) | GBA1LMNAPYGMSIPYGL | |
| SCHEMBL18916391 | 0.93 | GBA1 (0.38) | GBA1LMNAPYGMSIPYGL | |
| SCHEMBL16258712 | 0.77 | PYGM (0.33) | GBA1LMNAPYGMSIPYGL | |
| SCHEMBL13994642 | 0.71 | SLC5A1 (0.36) | SI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2535345-A1 | Anticancer nucleoside analogs | BioCryst Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | GBA1 341/4885LMNA 1314/4885PYGM 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.